WHO ICTRP trial
Supplemental Benefit of Angiotensin II Receptor Blocker in Hypertensive Patients…
JPRN-UMIN000000561 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000000561 |
|---|---|
| Public title | Supplemental Benefit of Angiotensin II Receptor Blocker in Hypertensive Patients with Stable Heart Failure using Olmesartan |
| Scientific title | Supplemental Benefit of Angiotensin II Receptor Blocker in Hypertensive Patients with Stable Heart Failure using Olmesartan - SUPPORT Trial |
| Primary sponsor | Tohoku Heart Failure Association The SUPPORT Study Group |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not selected |
| Countries | Japan |
| Conditions | Chronic Heart Failure |
| Interventions | Olmesartan 5-40mg daily, during the study period. Control |
| Registration date | Dec 26, 2006 |
| Target size | 1000 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: